i think obese people will want to get skinny i think health is something people care about and obsessed over i think more singles will live longer than married couples i think we will get lesser babies overtime.

Verdict: A Watch-List Setup, Not a Trade — Wait for the RSI to Cross 40

The idea is a demand narrative — health obsession, longer single lifespans, fewer babies — routed through six loosely related names, and the honest answer today is that there is nothing to buy yet. The setup's strongest point is that five of the six tickers are already in the oversold zone (CARE 31.7, LIVE 27.6, LOB 24.6, LYV 35.2, PPLI 35.9 on the RSI), with only an RSI recovery above 40 and a support reclaim left before entries arm. The strongest point against is that the rules did not trigger once in the last 24 months across 493 daily bars, and the ownership evidence runs the wrong way — LYV insiders were net open-market sellers of roughly $26.2M in the June 30, 2026 filing period, versus small net buying at HCAT and LIVE. The fundamentals are also a mixed bag: HCAT's margin improvement came alongside a shrinking top line ($70.5M in Q2 2026, below its 2023 run-rate of roughly $73.9M), while LYV flipped to a 3.8% net margin but carries $7.6B of long-term debt against just $271M of equity. The verdict would flip to actionable if the RSI (14) on the oversold names crosses back above 40 while each close holds its nearest support. Until then, this is a watch-list idea, not an entry.

Trade now: staged and waiting — five of six names are already oversold, none have fired

There is nothing to buy today, and that is by design. This is a watch-list setup: the rules were evaluated on live daily bars but did not open an entry. On CARE, four of the five entry conditions are already in place — the RSI (14) sits at 31.7, below the 38 oversold threshold, and the last close of $30.58 is above the nearest support level at $30.41 — but the RSI has not crossed back above 40, so the trigger is not armed. The same is true for LIVE (RSI 27.6), LOB (RSI 24.6), LYV (RSI 35.2) and PPLI (RSI 35.9), all of which are already below 38. Only HCAT is far from the setup, with an RSI of 51.9 that would need to fall 13.9 points to reach the oversold zone. What "wait" means concretely: for the five oversold names, the next leg is the RSI recovering above 40 while the close holds above each ticker's nearest support and the MACD line crosses above its signal line. All three of those conditions are currently live-to-near, so entries could arm within days of a bounce — the RSI recover is the binding condition, sitting 4.8 to 15.4 points away depending on the name. Risk framing once triggered: each position carries a hard 2.0% stop loss and a 4.0% take profit, a roughly 2:1 reward-to-risk shape, with a 90-session time exit as the backstop and positions capped near 16.7% of the book each. Note that no robust parameter setup was established — the parameter search exceeded its time budget, so we run the rules as written rather than a tuned variant. One factual scope note: the historical evaluation of the longest windows could not complete because of data gaps in CARE and LIVE, so the evaluable sample is limited to roughly the last two years of daily bars. That does not change today's action — the plan is to wait for the live triggers, not to judge the setup on history.

The Demand Thesis Has Pockets of Real Financial Support

The idea argues a broad demand rotation — health obsession, longer single lifespans, fewer babies — and routes it through six names. Taken on its own terms, the strongest data points line up with that narrative. Health Catalyst (HCAT), the most direct health-care exposure in the basket, improved its operating margin by nearly 99 percentage points quarter over quarter, from roughly -150.5% in the March quarter to -51.8% in the June 2026 quarter, and its net margin improved similarly, from -156.9% to -57.5%. Free cash flow also turned briefly positive at $18.2M in Q1 2026. If the thesis's "people care about health" demand claim has any real expression, it is in that accelerating fundamental inflection. Live Nation (LYV), the consumer-discretionary experiential play, is doing what a demand-driven name should: revenue grew 8.8% year over year to $25.2B in FY2025, net margin flipped from -10.3% in Q1 2026 to +3.8% in Q2, and return on equity sits at 357.6% for the June quarter — an extreme figure reflecting its thin $271M equity base, but still the 97th percentile among Communication Services peers. Free cash flow for the full year was $333.6M. People Inc (PPLI) also swung to a 116.1% net margin in Q2 2026 from -17.0% the prior quarter, with operating margin improving 6.2 points. The banking pair, Carter Bankshares (CARE) and Live Oak (LOB), is steadier than spectacular. LOB generated $143.5M of free cash flow in FY2025 — the 77th percentile among Financials peers — with return on equity of 8.5%, and its quarterly return on equity has been grinding up (2.35% to 2.80% between Q1 and Q2 2026). CARE posted 4.6% revenue growth and 7.5% return on equity for FY2025, both above the Financials median, and its share count has actually fallen from 26.5M in 2019 to 22.2M — a management team shrinking the float, not diluting it. One caution on framing: the entry rules did not trigger during the evaluated 24-month window over 493 daily bars, so this is a watch-list setup, not an active signal. That does not reflect a trust deficit — it means the RSI dip-below-38, recovery-above-40, support-reclaim and MACD crossover conditions simply have not aligned yet. What the fundamentals above give the reader is the reason to keep these six names on the watch list at all.

Where the Thesis Meets Hard Pushback

The bear case starts with the scoreboard: the rules did not trigger in the last 24 months across 493 evaluated daily bars, and a 60-month attempt failed on a data-engine error. The entry may simply be far from current market conditions. Meanwhile the parameter search returned no robust setup — the optimization exceeded its time budget, so no nearby-parameter recommendation was established. The reader is being asked to watch, not to act. Ownership posture is mixed at best. Live Nation insiders were net open-market sellers to the tune of $26.2M across seven reporting holders as of the June 30, 2026 filing period — the largest insider sell program in this basket by an order of magnitude. PPLI insiders also sold a net $278,801. Carter Bankshares shows $231,898 of net insider selling too. Only HCAT ($105,439) and LIVE ($55,041, from a single reporter — a low-conviction datapoint) show net buying. Management pay at LYV is steep: CEO Michael Rapino earned $22.6M in FY2025, with the CFO at $6.2M. The weakest fundamentals sit exactly where the thesis leans hardest. Health Catalyst is still deeply unprofitable: FY2025 net income of -$178.0M on $311.1M revenue, a 57.2% net margin loss, and return on equity of -72.4% — the 11th percentile among IT peers. Shares outstanding rose from 36.7M in 2019 to 74.6M by mid-2026, a continuous dilution treadmill that undercuts any "demand tailwind" framing. HCAT pays no dividend, and neither do LYV, LIVE, or PPLI. PPLI itself shrank revenue 8.7% year over year in FY2025 and remains operating-margin negative. LIVE VENTURES posted 5.9% revenue decline for its FY2025 with just $8.8M of cash on a $386M balance sheet — thin liquidity for a leveraged consumer name. Even the "improving" stories are fragile. HCAT's Q2 2026 revenue of $70.5M is below its 2023 quarterly run-rate of ~$73.9M, so the margin gain came alongside a shrinking top line. LYV carries $7.6B of long-term debt against $271M of equity, a current ratio…

Scores

• Conviction score breakdown: 45
• Thesis support: 40
• Trade readiness: 35
• Risk quality: 50
• Trigger proximity: 55
• Fundamentals trend: 45

Watch items

• CARE — RSI (14)
• CARE — Close vs nearest support
• HCAT — RSI (14)
• LIVE — RSI (14)
• LIVE — Close vs nearest support
• LOB — RSI (14)
• LYV — RSI (14)
• PPLI — RSI (14)
• LYV — Net insider open-market activity (next quarterly filing)